Literature DB >> 6833014

Accelerated fractionation vs hyperfractionation: rationales for several treatments per day.

H D Thames, L J Peters, H R Withers, G H Fletcher.   

Abstract

Treatment with several doses per day offers the prospect of a significant therapeutic gain using readily available low LET beams. These regimens can be classified as either accelerated fractionation or hyperfractionation according to their rationales. With accelerated fractionation a conventional number of dose fractions is delivered in a significantly shortened overall treatment time in order to reduce the opportunity for tumor cell regeneration during treatment. With hyperfractionation, on the other hand, a large number of significantly reduced dose fractions is used to give a greater total dose in a conventional overall treatment time. The rationale for this strategy is threefold: 1) increased opportunity for tumor cell redistribution and reoxygenation between dose fractions: 2) a possibly lower oxygen enhancement ratio with small incremental doses; and 3) different sparing of late reacting normal tissues with small dose fractions. A review of the published clinical experience with multiple fractions per day treatment reveals few studies of either pure accelerated fractionation or hyperfractionation since both are limited by acute normal tissue reactions. This has led to a variety of hybrid regimens, some of which have no clear rationale. The choice between accelerated fractionation and hyperfractionation is determined by the regenerative capability of tumor clonogens during treatment. A method of selection based on potential doubling times is presented.

Entities:  

Mesh:

Year:  1983        PMID: 6833014     DOI: 10.1016/0360-3016(83)90089-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  35 in total

1.  Pediatric brainstem glioma. Post-radiation clinical and MR follow-up.

Authors:  R R Smith; R A Zimmerman; R J Packer; D B Hackney; L T Bilaniuk; L N Sutton; H I Goldberg; R I Grossman; L Schut
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

2.  Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study.

Authors:  D S Fulton; R C Urtasun; I Scott-Brown; E S Johnson; B Mielke; B Curry; D Huyser-Wierenga; J Hanson; M Feldstein
Journal:  J Neurooncol       Date:  1992-09       Impact factor: 4.130

3.  Multiple-fraction-per-day external beam radiotherapy for adults with supratentorial malignant gliomas.

Authors:  E C Halperin
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

Review 4.  Exploring two two-edged swords.

Authors:  David J Brenner
Journal:  Radiat Res       Date:  2012-06-27       Impact factor: 2.841

Review 5.  21 years of biologically effective dose.

Authors:  J F Fowler
Journal:  Br J Radiol       Date:  2010-07       Impact factor: 3.039

6.  Pathologic complete response may not represent the optimal surrogate for survival after preoperative therapy for esophageal cancer.

Authors:  A William Blackstock; Mabea Aklilu; James Lovato; Michael R Farmer; Girish Mishra; Susan A Melin; Timothy Oaks; Kim Geisinger; Edward A Levine
Journal:  Int J Gastrointest Cancer       Date:  2006

7.  NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.

Authors:  Arif N Ali; Peixin Zhang; W K Alfred Yung; Yuhchyau Chen; Benjamin Movsas; Raul C Urtasun; Christopher U Jones; Kwang N Choi; Jeff M Michalski; A Jennifer Fischbach; Arnold M Markoe; Christopher J Schultz; Marta Penas-Prado; Madhur K Garg; Alan C Hartford; Harold E Kim; Minhee Won; Walter J Curran
Journal:  J Neurooncol       Date:  2018-02-05       Impact factor: 4.130

Review 8.  Strategies in the treatment of diffuse pontine gliomas: the therapeutic role of hyperfractionated radiotherapy and chemotherapy.

Authors:  M T Jennings; M L Freeman; M J Murray
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

9.  Gender-related differences in repopulation and early tumor response to preoperative radiotherapy in rectal cancer patients.

Authors:  Anna Gasinska; Piotr Richter; Zbigniew Darasz; Joanna Niemiec; Krzysztof Bucki; Krzysztof Malecki; Andrzej Sokolowski
Journal:  J Gastrointest Surg       Date:  2011-06-25       Impact factor: 3.452

10.  PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice.

Authors:  M Busk; L S Mortensen; M Nordsmark; J Overgaard; S Jakobsen; K V Hansen; J Theil; J F Kallehauge; F P D'Andrea; T Steiniche; M R Horsman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-18       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.